MYD88 L265P mutations occur in approximately 30% of ABC diffuse large B cell lymphomas (ABC DLBCL) and 90% of Waldenstrom’s macroglobulinemia (WM)

MYD88 L265P mutations occur in ~2.9-6.25% of CLL, although role in CLL not clearly understood

MYD88 L265P mutations: associated with higher viability

Cells treated with ND-2158 + ibrutinib had significantly lower viability compared to cells treated with ND-2158 alone

Co-culturing CLL cells and NIH3T3 cells expressing CD40L, with and without CpG stimulation in one WT MYD88 CLL patient resulted in significant induction of Ki67 expression, which was reduced by combination of either ND-2110 or 2158 with ibrutinib.